Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AT-05
- Development stage
- Unknown
- Lead developer
- Attralus
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
AT-05 is a diagnostic radiopharmaceutical agent that consists of a pan-amyloid binding peptide labeled with technetium-99m (Tc-99m). It is designed for use with single-photon emission computerized tomography (SPECT) imaging to detect amyloid deposits in patients suspected of systemic amyloidosis. The pan-amyloid peptide component enables binding to multiple types of amyloid deposits, supporting broad screening and diagnosis. The drug aims to make amyloidosis imaging more accessible by using Tc-99m, which is widely available for SPECT imaging. Development has been reported by both Amylon Therapeutics and Attralus[1][2].
- Brand names
- AT-05AT05AT 05
- Other names
- AT05AT-05AT 05Amylon Therapeutics AT-05
Beyond the preview
Go deeper on AT-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AT-05.